GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (NAS:ONVO) » Definitions » Shiller PE Ratio

Organovo Holdings (Organovo Holdings) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Organovo Holdings Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Organovo Holdings Shiller PE Ratio Historical Data

The historical data trend for Organovo Holdings's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings Shiller PE Ratio Chart

Organovo Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Organovo Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Organovo Holdings's Shiller PE Ratio

For the Biotechnology subindustry, Organovo Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organovo Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's Shiller PE Ratio falls into.



Organovo Holdings Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Organovo Holdings's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Organovo Holdings's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.4/129.4194*129.4194
=-0.400

Current CPI (Dec. 2023) = 129.4194.

Organovo Holdings Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1.600 99.695 -2.077
201406 -1.600 100.560 -2.059
201409 -2.200 100.428 -2.835
201412 -1.800 99.070 -2.351
201503 -2.000 99.621 -2.598
201506 -2.000 100.684 -2.571
201509 -2.400 100.392 -3.094
201512 -2.200 99.792 -2.853
201603 -1.812 100.470 -2.334
201606 -1.800 101.688 -2.291
201609 -2.000 101.861 -2.541
201612 -1.800 101.863 -2.287
201703 -2.000 102.862 -2.516
201706 -2.000 103.349 -2.505
201709 -1.800 104.136 -2.237
201712 -1.400 104.011 -1.742
201803 -1.400 105.290 -1.721
201806 -1.400 106.317 -1.704
201809 -1.000 106.507 -1.215
201812 -1.200 105.998 -1.465
201903 -1.200 107.251 -1.448
201906 -1.000 108.070 -1.198
201909 -1.000 108.329 -1.195
201912 -0.600 108.420 -0.716
202003 -0.400 108.902 -0.475
202006 -0.400 108.767 -0.476
202009 -1.360 109.815 -1.603
202012 -0.370 109.897 -0.436
202103 -0.300 111.754 -0.347
202106 -0.290 114.631 -0.327
202109 -0.400 115.734 -0.447
202112 -0.400 117.630 -0.440
202203 -0.220 121.301 -0.235
202206 -0.370 125.017 -0.383
202209 -0.380 125.227 -0.393
202212 -0.370 125.222 -0.382
202303 -0.850 127.348 -0.864
202306 -0.460 128.729 -0.462
202309 -0.460 129.860 -0.458
202312 -0.400 129.419 -0.400

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Organovo Holdings  (NAS:ONVO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Organovo Holdings Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Organovo Holdings (Organovo Holdings) Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
Executives
David Gobel director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi director C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess officer: President, CFO and PFO 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen officer: General Counsel & Secretary 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner officer: Chief Scientific Officer 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig officer: President and CFO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy director, officer: Executive Chairman 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes officer: Chief Medical Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins officer: EVP, Research & Development 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch director, officer: CEO & President 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075